Nontuberculous Mycobacterial Infections Pipeline Analysis 2025 by DelveInsight | Mannkind Corporation, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics

Posted on
by

Nontuberculous Mycobacterial Infections Pipeline Analysis 2025 by DelveInsight | Mannkind Corporation, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics
Nontuberculous Mycobacterial Infections Pipeline Analysis
DelveInsight’s, “Nontuberculous Mycobacteria Infections – Pipeline Insight, 2025,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Nontuberculous Mycobacteria Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Nontuberculous Mycobacterial Infections Pipeline constitutes 10+ key companies continuously working towards developing 10+ Nontuberculous Mycobacterial Infections treatment therapies, analyzes DelveInsight.

Nontuberculous Mycobacterial Infections Overview:

Nontuberculous Mycobacterial (NTM) infections are caused by environmental mycobacteria distinct from those responsible for tuberculosis or leprosy. These organisms are commonly present in soil, water, and dust, and typically affect people with weakened immune systems or pre-existing lung disorders. The incidence of NTM infections is rising, particularly in developed nations.

The pulmonary form is the most prevalent, especially in individuals with chronic lung diseases such as COPD, bronchiectasis, or cystic fibrosis. Symptoms depend on the site of infection but often include a persistent cough, fatigue, weight loss, and hemoptysis. Other manifestations may involve swollen lymph nodes, skin lesions, or abscesses.

NTM bacteria enter through inhalation or breaks in the skin but are generally not contagious. They can persist in the body by forming biofilms and residing within host cells, making eradication challenging. People with compromised immunity, including those with HIV or undergoing immunosuppressive therapy, face a higher risk of infection.

Diagnosis requires a combination of clinical assessment, imaging, and laboratory tests. Imaging often reveals lung damage, while cultures or molecular testing identify the specific bacterial strain. Treatment is complex, long-term, and typically involves multidrug antibiotic regimens such as macrolides, rifamycins, and ethambutol for more than a year. In severe cases, surgical intervention and management of underlying conditions may be necessary.

Download our report @ https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

“Nontuberculous Mycobacterial Infections Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nontuberculous Mycobacterial Infections Therapeutics Market.

Key Takeaways from the Nontuberculous Mycobacterial Infections Pipeline Report

  • DelveInsight’s Nontuberculous Mycobacterial (NTM) Infections pipeline report showcases a dynamic landscape, with over 10 companies working on more than 10 potential therapies for NTM treatment.

  • In January 2025, the FDA granted Orphan Drug Designation to MRX-5, a novel benzoxazole antibiotic for NTM infections, offering incentives such as tax credits and market exclusivity to support rare disease drug development.

  • In May 2024, MannKind Corporation’s clofazimine inhalation suspension (MNKD-101) received Fast Track designation from the FDA to accelerate development for NTM lung disease. Shortly before, in April 2024, the FDA had cleared its IND application to begin a global Phase 3 trial (ICoN-1).

  • Additionally, in January 2024, pravibismane was awarded its second Orphan Drug Designation for NTM infections, having shown strong efficacy in both acute and chronic infection models.

  • Key players driving innovation in this space include MannKind Corporation, Matinas BioPharma, Spero Therapeutics, Crestone, Vast Therapeutics, among others, all actively advancing novel therapies.

  • Prominent candidates under development for NTM infections include MNKD-101, MAT2501, and several others across different clinical stages.

Nontuberculous Mycobacterial Infections Pipeline Analysis

The Nontuberculous Mycobacterial Infections pipeline insights report 2025, provides insights into:

  • Provides comprehensive insights into key companies developing therapies in the Nontuberculous Mycobacterial Infections Market.

  • Categorizes Nontuberculous Mycobacterial Infections therapeutic companies by development stage: early, mid, and late-stage.

  • Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

  • Reviews emerging Nontuberculous Mycobacterial Infections drugs under development based on:

    • Stage of development

    • Nontuberculous Mycobacterial Infections Route of administration

    • Target receptor

    • Monotherapy vs. combination therapy

    • Nontuberculous Mycobacterial Infections Mechanism of action

    • Molecular type

  • Offers detailed analysis of:

    • Company-to-company and company-academia collaborations

    • Nontuberculous Mycobacterial Infections Licensing agreements

    • Funding and investment activities supporting future Nontuberculous Mycobacterial Infections market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Nontuberculous Mycobacteria Infections Emerging Drugs

  • MNKD-101: Mannkind Corporation

  • MAT2501: Matinas BioPharma

Nontuberculous Mycobacterial Infections Companies

Over 10 leading companies are currently working on developing therapies for Nontuberculous Mycobacterial (NTM) infections, with MannKind Corporation advancing the most progressed candidate, now in Phase III trials.

DelveInsight’s report covers around 10+ products under different phases of Nontuberculous Mycobacterial Infections clinical trials like

  • Nontuberculous Mycobacterial Infections Late stage Therapies (Phase III)

  • Nontuberculous Mycobacterial Infections Mid-stage Therapies (Phase II)

  • Nontuberculous Mycobacterial Infections Early-stage Therapies (Phase I)

  • Nontuberculous Mycobacterial Infections Pre-clinical and Nontuberculous Mycobacterial Infections Discovery stage Therapies

  • Nontuberculous Mycobacterial Infections Discontinued & Inactive Therapies

Nontuberculous Mycobacterial Infections pipeline report provides the Nontuberculous Mycobacterial Infections therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Nontuberculous Mycobacterial Infections Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Nontuberculous Mycobacterial Infections Therapies and Key Nontuberculous Mycobacterial Infections Companies: Nontuberculous Mycobacterial Infections Clinical Trials and recent advancements

Nontuberculous Mycobacterial Infections Pipeline Therapeutic Assessment

• Nontuberculous Mycobacterial Infections Assessment by Product Type

• Nontuberculous Mycobacterial Infections By Stage

• Nontuberculous Mycobacterial Infections Assessment by Route of Administration

• Nontuberculous Mycobacterial Infections Assessment by Molecule Type

Download Nontuberculous Mycobacterial Infections Sample report to know in detail about the Nontuberculous Mycobacterial Infections treatment market @ Nontuberculous Mycobacterial Infections Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Nontuberculous Mycobacterial Infections Current Treatment Patterns

4. Nontuberculous Mycobacterial Infections – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Nontuberculous Mycobacterial Infections Late-Stage Products (Phase-III)

7. Nontuberculous Mycobacterial Infections Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Nontuberculous Mycobacterial Infections Discontinued Products

13. Nontuberculous Mycobacterial Infections Product Profiles

14. Nontuberculous Mycobacterial Infections Key Companies

15. Nontuberculous Mycobacterial Infections Key Products

16. Dormant and Discontinued Products

17. Nontuberculous Mycobacterial Infections Unmet Needs

18. Nontuberculous Mycobacterial Infections Future Perspectives

19. Nontuberculous Mycobacterial Infections Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Nontuberculous Mycobacterial Infections Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/